Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900839 | 0.87 | HDAC4 (0.40) | HDAC4HDAC1 | |
| SCHEMBL9385662 | 0.87 | HDAC4 (0.37) | HDAC4HDAC1 | |
| SCHEMBL4898837 | 0.71 | CHRNB2 (0.32) | — | |
| SCHEMBL16653312 | 0.70 | — | — | |
| SCHEMBL3838902 | 0.60 | MAP3K14 (0.31) | — | |
| SCHEMBL11779069 | 0.59 | — | — | |
| SCHEMBL85907 | 0.58 | — | — | |
| SCHEMBL10841728 | 0.58 | — | — | |
| SCHEMBL5386313 | 0.57 | DAO (0.35) | — | |
| SCHEMBL11354962 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024258728-A2 | EPIDITHIODIKETOPIPERAZINE ANALOGS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3448389-B1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3022202-B1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | NOVARTIS AG (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10183025-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2019-01-22 | — | — | US | disclosed |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2018-01-25 | — | — | US | disclosed |
| US-9763957-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| EP-3022202-A1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008230-A1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| WO-2008134035-A1 | ALPHA-UNSUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-A] PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008134035-A1 | ALPHA-UNSUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-A] PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-4577023-A | Diazabicyclo (2,2,2) octadiones | STAMICARBON B.V. (NL) | 1986-03-18 | — | — | US | disclosed |
| EP-0080245-A1 | Diazabicyclo(2,2,2)octadiones and process for their preparation | STAMICARBON B.V. (NL) | 1983-06-01 | — | — | EP | disclosed |
| US-3951980-A | 3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes | STANFORD RESEARCH INSTITUTE (US) | 1976-04-20 | — | — | US | disclosed |
| US-3947445-A | Diazabicyclooctanes and diazabicycloheptanes | STANFORD RESEARCH INSTITUTE (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | HDAC4 2586/4885HDAC1 2666/4885 |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | HDAC4 3946/4885HDAC1 4041/4885 |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | CFB, TFPI, MAOB | HDAC4 3946/4885HDAC1 4041/4885 |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | HDAC4 2586/4885HDAC1 2666/4885 |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | HDAC4 3946/4885HDAC1 4041/4885 |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | HDAC4 3946/4885HDAC1 4041/4885 |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | HDAC4 3946/4885HDAC1 4041/4885 |
| US-10183025-B2 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | HDAC4 2586/4885HDAC1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.